Mads Kjølby is an MD, PhD, consultant in clinical pharmacology, and clinical associate professor in pharmacology. He was part of the team that identified a role for Vps10p-domain receptors outside the nervous system. He has run several clinical studies including an international drug repurposing trial during the corona pandemic. He has experience with clinical trials in children and adults, in acute situations, and in basal physiological conditions.
As an associate professor, and PI in the ODIN project BALDER, he has built a strong team that uses large scale genomic data and does drug target identification. He is a co-founder of Vesper Bio, where he has the role of as VP of Research and Development.